Unicycive Therapeutics, Inc.
UNCY evidence brief
What we can confirm
- Market Cap:
- $144.9M
What it means
What to watch
Prepared research question
What matters most for UNCY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · UNCY
Unicycive Therapeutics is a clinical-stage biotech company focused on developing therapies for kidney disease, with two lead candidates: oxylanthanum carbonate (a phosphate binder for dialysis patients) and UNI-494 (a potential first-in-class treatment for acute kidney injury).
Key risk: Regulatory delay for OLC
Market Cap
$144.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Unicycive Therapeutics is a clinical-stage biotech company focused on developing therapies for kidney disease, with two lead candidates: oxylanthanum carbonate (a phosphate binder for dialysis patients) and UNI-494 (a potential first-in-class treatment for acute kidney injury).
- Cash & equivalents of $44.2M as of 2026-06-30 [sec].
- Net loss of -$1.7M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $53.3M as of 2026-06-30 [sec].
- Expects to resubmit NDA for oxylanthanum carbonate after FDA inspection of third-party manufacturing vendor [news · 2026-08-12].
- UNI-494 is described as having potential to be a first-in-class drug for acute kidney injury [sec_mda · 2026-08-12].
What works
- Cash runway expected into 2027, with unaudited cash, cash equivalents, and marketable securities of $61.4M as of June 30, 2026 [news · 2026-08-12].
- Company has two distinct kidney-focused programs addressing high unmet needs: hyperphosphatemia in dialysis and acute kidney injury [sec_mda · 2026-03-30].
- Management team described as having a broad network, expertise, and successful track record in the biopharmaceutical industry [sec_mda · 2026-08-12].
What to weigh
- Company anticipates needing to raise substantial additional capital, with requirements depending on many factors including clinical trial costs and regulatory outcomes [sec_mda · 2026-08-12].
- Net loss of -$1.7M as of 2026-06-30 indicates ongoing operating losses [sec].
- Resubmission of the OLC NDA is contingent on successful FDA inspection of a third-party manufacturing vendor, introducing regulatory uncertainty [news · 2026-08-12].
From the filings
Quoted directly from source documents.
Cash position and runway
“As of June 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $61.4 million, with expected runway into 2027”
News · August 12, 2026
UNI-494 first-in-class potential
“If approved, UNI-494 has the potential to be a first-in-class drug for the treatment of AKI.”
SEC MD&A · August 12, 2026
Need for additional capital
“We anticipate that we will need to raise substantial additional capital, the requirements for which will depend on many factors”
SEC MD&A · August 12, 2026
Risks & what to watch (3)›
Key risks
- Regulatory delay for OLC — NDA resubmission depends on FDA inspection of third-party manufacturer; outcome uncertain [news · 2026-08-12].
- Capital needs — Company expects to need substantial additional capital; future dilution or debt risk [sec_mda · 2026-08-12].
- Operating losses — Net loss of -$1.7M as of 2026-06-30; no approved products generating revenue [sec].
What to watch
- FDA inspection outcome and timing of OLC NDA resubmission [news · 2026-08-12].
- Progress of UNI-494 clinical development for acute kidney injury [sec_mda · 2026-08-12].
- Company's ability to raise additional capital and manage cash runway into 2027 [news · 2026-08-12].
Sources: News · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Unicycive Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Unicycive Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of Apr 30, 2026- % of float
- 8.8%
- Days to cover
- 4.1
- Shares short
- 2,161,598
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
UNCY short interestGovernance
Frequently asked questions
What is the AI investment thesis for Unicycive Therapeutics, Inc.?
Unicycive Therapeutics is a clinical-stage biotech company focused on developing therapies for kidney disease, with two lead candidates: oxylanthanum carbonate (a phosphate binder for dialysis patients) and UNI-494 (a potential first-in-class treatment for acute kidney injury).
Who is the CEO of Unicycive Therapeutics, Inc.?
Dr. Shalabh K. Gupta M.D., MPA is the chief executive officer of Unicycive Therapeutics, Inc. (UNCY).
Where is Unicycive Therapeutics, Inc. headquartered?
Unicycive Therapeutics, Inc. (UNCY) is headquartered in Mountain View, CA, United States.
What therapeutic areas does Unicycive Therapeutics, Inc. focus on?
Unicycive Therapeutics, Inc. develops therapies across Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.